Source:http://linkedlifedata.com/resource/pubmed/id/15335102
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
2004-8-31
|
pubmed:abstractText |
Single dose 3-nitropropionic acid (3-NPA) 24 hr before global ischemia improves neuronal survival in both, neocortex and hippocampus ('chemical preconditioning'). Neuronal survival after transient global ischemia requires new protein synthesis during recovery, especially of those with anti-apoptotic function. Bcl-2-protein is expressed in neurons that survive cerebral ischemia and may parallel the time course of tolerance after ischemic preconditioning. With this study we examined whether differences in bcl-2-protein expression compared to baseline may be involved in the induction of ischemic tolerance using 3-NPA. Male Wistar rats received either a single intraperitoneal (i.p.) dose of 3-NPA (20 mg/kg), and were observed for 3 (n = 4), 12 (n = 5) or 24 hours (n = 5) or the same amount of vehicle and were observed for 24 h (n = 8, controls). Immunohistochemistry allowed to compare the intensity of bcl-2 immunoreactivity at three subsequent time points in hippocampus, dentate gyrus and parietal neocortex with that of control animals. A single dose of 3-NPA caused a significant increase of bcl-2 protein immunoreactivity in hippocampal neurons, i.e. CA 1 (5 out of 5 animals, p = 0.003), CA 3 (5/5, p = 0.003), CA 4 (4/5, p = 0.025), and neocortex (5/5, p = 0.004), in a time dependent manner over a period of 24 hr after injection. Neuronal bcl-2 protein expression in CA 2 and dentate gyrus remained unchanged. The data suggest a possible role of bcl-2-protein in chemical induction of ischemic tolerance using a single subtoxic dose of 3-NPA. Bcl-2-protein expression may be initiated by increased levels of reactive oxygen species (ROS) after 3-NPA administration, as shown by others. Additional bcl-2 protein may then be available to (1) control postischemic ROS burst, (2) protect the mitochondrial membranes, and (3) inhibit pro-apoptotic mechanisms.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0065-1419
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
89
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
63-6
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15335102-Adaptation, Physiological,
pubmed-meshheading:15335102-Animals,
pubmed-meshheading:15335102-Brain,
pubmed-meshheading:15335102-Brain Ischemia,
pubmed-meshheading:15335102-Cell Survival,
pubmed-meshheading:15335102-Injections, Intraperitoneal,
pubmed-meshheading:15335102-Ischemic Preconditioning,
pubmed-meshheading:15335102-Male,
pubmed-meshheading:15335102-Neurons,
pubmed-meshheading:15335102-Nitro Compounds,
pubmed-meshheading:15335102-Propionic Acids,
pubmed-meshheading:15335102-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:15335102-Rats,
pubmed-meshheading:15335102-Rats, Wistar
|
pubmed:year |
2004
|
pubmed:articleTitle |
Pharmacological preconditioning in global cerebral ischemia.
|
pubmed:affiliation |
Institut of Neurosurgical Pathophysiology, Johannes Gutenberg-University, Mainz, Germany.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Evaluation Studies
|